

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
ANDA 62-756 / S-013

Name: Primaxin® ADD-Vantage®
(Imipenem-Cilastatin Sodium for Injection)

Sponsor: Merck Research Laboratories

Approval Date: February 18, 1992

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 62-756 / S-013

CONTENTS

Reviews / Information Included in this Review
--

Approval Letter	X
Tentative Approval Letter	
Labeling	
Labeling Reviews	
Medical Review(s)	
Chemistry Review	X
Bioequivalence Review(s)	
Statistical Review(s)	
Microbiology Review	
Administrative Documents	
Correspondence	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 62-756 / S-013

APPROVAL LETTER

AADA 62-756/S-013

Merck Sharp & Dohme Research Laboratories
Attn: Ronald A. Salerno, Ph.D.
Associate Director
Regulatory Liason
Sumneytown Pike
West Point, PA 19486

FEB 18 1992

Dear Sir:


Reference is made to your supplemental antibiotic drug application submitted pursuant to Section 314.70 of the Regulations, dated August 19, 1991, regarding your abbreviated antibiotic application for Primaxin® ADD-Vantage® (Imipenem-Cilastatin Sodium for Injection, MSD)

The supplemental application provides for reducing intentional overage for Sterile Imipenem and Sterile Cilastatin Sodium drug substances to — %.

We have completed the review of this supplemental application and it is approved. Our letter of January 8, 1987 detailed the conditions relating to the approval of this abbreviated application.

The material submitted is being retained as part of your application.

Sincerely yours,



Michael G. Beatrice
Director
Division of Chemistry II
Office of Generic Drugs
Center for Drug Evaluation and Research

cc: AADA # 62-756/S-013

DUP/Division File

HFD-600/RF

HFC-130/JAllen

HFD-635/JHarrison/EDuffy

HFD-635/MAnderson

R/D initialed by JHarrison

mw/2/14/92/62756s.013

F/T by mw/2/14/92

SUPPLEMENT APPROVAL

APPEARS THIS WAY
ON ORIGINAL

EDuffy
12/14/92
Martz Anderson
2/14/92
JHarrison
12/14/92

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 62-756 / S-013

CHEMISTRY REVIEW

AADA 62-756/S-013

NAME AND ADDRESS OF APPLICANT:

Merck Sharp & Dohme Research Laboratories
Attn: Ronald A. Salerno, Ph.D.
Associate Director
Regulatory Liason
Sumneytown Pike
West Point, PA 19486

Contact:

Ronald A. Salerno, Ph.D.
Associate Director
Regulatory Liason
(215) 834-2958
or
Kenneth R. Brown, M.D.
(215) 834-2552

PURPOSE OF AMENDMENT/SUPPLEMENT

The supplemental application provides for reducing intentional overage for Sterile Imipenem and Sterile Cilastatin Sodium drug substances to —%.

DATE OF SUBMISSION

August 19, 1991

PHARMACOLOGICAL CATEGORY

Antibiotic

TRADE NAME

Primaxin® I.V. ADD-Vantage®

NONPROPRIETARY NAME

Imipenem-Cilastatin Sodium

DOSAGE FORM

Powder for reconstitution

POTENCY

250, 500 mg

RX OR OTC

R

SAMPLES

N/A

RELATED IND/NDA/DMF

50-587 Primaxin® IV
50-630 Primaxin® IM

STERILIZATION

N/A

LABELING

N/A

BIOEQUIVALENCY STATUS

N/A

ESTABLISHMENT INSPECTION

N/A

COMPONENTS, COMPOSITION, MANUFACTURING

APPROVED COMPOSITION

COMPONENT	250/250	500/500
STERILE IMIPENEM MONOHYDRATE	— mg *	— mg *
STERILE CILASTATIN SODIUM	— mg *	— mg *
STERILE SODIUM BICARBONATE	— mg	— mg
	— mg	— mg

* equivalent to 250 mg and —% overage for Imipenem & Cilastatin

* equivalent to 500 mg and —% overage for Imipenem & Cilastatin

PROPOSED COMPOSITION

COMPONENT	250/250	500/500
STERILE IMIPENEM MONOHYDRATE	— mg *	— mg *
STERILE CILASTATIN SODIUM	— mg *	— mg *
STERILE SODIUM BICARBONATE	10 mg	— mg
	— mg	— mg

* equivalent to 250 mg and —% overage for Imipenem & Cilastatin

* equivalent to 500 mg and —% overage for Imipenem & Cilastatin

CONTROLS

N/A

PACKAGING

N/A

STABILITY

Stability data indicate that each component has acceptable stability - e.g. data reported in annual report of 1/90.

REMARKS AND CONCLUSION

The proposed reduction of intentional overage from -% to —% for Sterile Imipenem and Sterile Cilastatin Sodium drug substances is based upon statistical analysis of — lots of drug substance produced in 1990. The drug substance assay values for both components were _____

Reducing the intentional overage to — % will serve to bring the assays closer to — .

RECOMMENDATION - APPROVABLE

RECOMMENDATION - APPROVABLE

RECALLS

Reviewer

Date Completed

Eric P. Duffy

cc: AADA # 62-756/S-013

Review Chemist's name: Eric P. Duffy *EDUFFY 2/19/92*

Supervisor's name: John D. Harrison *John D Harrison 4/6/92*

The application covered by this review was taken in date order of receipt.

YES

NO

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
ANDA 62-756 / S-013

CORRESPONDENCE

These copies are OFFICIAL FDA Copies
not desk copies.

Vol. 3.1

MERCK SHARP & DOHME RESEARCH LABORATORIES

DIVISION OF MERCK & CO., INC.
WEST POINT, PENNSYLVANIA 19486

RONALD A. SALERNO, PH.D.
ASSOCIATE DIRECTOR
REGULATORY AFFAIRS

August 19, 1991

(215) 834-2958
(215) 661-5000
FAX (215) 834-2962

NDA NO. _____ REF. NO. SC-013

NDA SUPPL FOR CONTROL REVISION

RECEIVED

AUG 21 1991

GENERIC DRUGS

Mr. John D. Harrison, Chief
Antibiotic Drug Review Branch
HFD-635, Room 17B-31
Division of Generic Drugs
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Dear Mr. Harrison:

Supplemental New Drug Application
~~ANDA 62-756: Primaxin® I.V. ADD-Vantage®~~
(Imipenem-Cilastatin Sodium for Injection, MSD)

Cross-Referenced Supplement
NDA 50-587: PRIMAXIN® I.V.
(Imipenem-Cilastatin Sodium for Injection, MSD)

Pursuant to Section 505(b) of the Food, Drug and Cosmetic Act and in accordance with 21 CFR 314.50 and 21 CFR 314.70(b), we submit for your approval, a supplement to ANDA 62-756.

As indicated in the attached Form 356h, the supplemental application provides for changes in Item 3 of the approved New Drug Application for Primaxin® I.V. ADD-Vantage®.

This supplemental application provides for the reduction of overage required for possible losses during the expiry from —% to —% for both Imipenem and Cilastatin Sodium. This reduction is based on the review of _____ stability and _____ data. Attachment I provides a statistical summary for — lots which contain the —% overage.

To facilitate your review, annotated and clean copies of the page describing the _____ composition are attached.

Please note that an identical supplement is also being submitted, under separate cover, to the Primaxin® I.V. (NDA 50-587) filed with the Anti-Infective Drug Products.


ORIGINAL

Mr. John Harrison, Chief
ANDA 62-756: Primaxin® I.V. ADD-Vantage®
Page 2

We consider the filing of this Supplemental New Drug Application to be a confidential matter, and request the Food and Drug Administration not to make its content, nor any future communications in regard to it public without first obtaining the written permission of Merck & Co., Inc.

Questions concerning this supplemental application should be directed to Dr. Ronald A. Salerno (215/834-2958) or, in my absence, to Kenneth R. Brown, M.D. (215/834-2552).

Sincerely yours,



Ronald A. Salerno, Ph.D.
Associate Director
Regulatory Affairs

ALS/cat
75H

Attachments

Certified No. P 856 788 916